REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.34 USD | -0.07% |
|
-3.89% | -20.11% |
Financials (USD)
| Sales 2024 * | 99.85M | Sales 2025 * | 253M | Capitalization | 706M |
|---|---|---|---|---|---|
| Net income 2024 * | -231M | Net income 2025 * | -96M | EV / Sales 2024 * | 6.06 x |
| Net cash position 2024 * | 102M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 2.17 x |
| P/E ratio 2024 * |
-2.9
x | P/E ratio 2025 * |
-8.19
x | Employees | 344 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on REGENXBIO Inc.
More recommendations
More press releases
| 1 day | -0.07% | ||
| 1 week | -3.89% | ||
| Current month | -0.07% | ||
| 1 month | -6.58% | ||
| 3 months | -17.78% | ||
| 6 months | -26.54% | ||
| Current year | -20.11% |
1 week
14.08
15.39
1 month
14.0817.52
Current year
11.8328.80
1 year
11.8328.80
3 years
11.8346.46
5 years
11.8355.23
10 years
7.0785.10
| Managers | Title | Age | Since |
|---|---|---|---|
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Vit Vasista
DFI | Director of Finance/CFO | 56 | 09-07-31 |
| Chief Tech/Sci/R&D Officer | - | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 21-09-02 |
David Stump
BRD | Director/Board Member | 74 | 15-10-14 |
| Director/Board Member | 71 | 15-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 14 M€ | -5.07% | ||
| 0.25% | 25 M€ | -2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 14.35 | -.--% | 424,737 |
| 24-05-30 | 14.35 | +1.70% | 582,425 |
| 24-05-29 | 14.11 | -5.68% | 328,943 |
| 24-05-28 | 14.96 | +0.27% | 270,479 |
| 24-05-24 | 14.92 | -0.27% | 309,684 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
14.34
USD
Average target price
39
USD
Spread / Average Target
+171.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.11% | 707M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- RGNX Stock
